![A comparison of Janus kinase inhibitor safety in rheumatoid arthritis - Nash - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library A comparison of Janus kinase inhibitor safety in rheumatoid arthritis - Nash - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/707a49fa-f7cd-4720-a119-f5d1a44c2c18/apl14127-fig-0001-m.jpg)
A comparison of Janus kinase inhibitor safety in rheumatoid arthritis - Nash - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library
![Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards - Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards -](https://acrabstracts.org/wp-content/uploads/2018/08/887_Paper_70044_abstract_113846_0.png)
Efficacy and Safety of the Novel Oral Janus Kinase (JAK) Inhibitor, Peficitinib (ASP015K), in a Phase 3, Double-Blind, Placebo-Controlled, Randomized Study of Patients with RA Who Had an Inadequate Response to Dmards -
![JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association](https://nationaleczema.org/wp-content/uploads/2021/01/JAK-Image-copy.png)
JAK Inhibitors Are Coming and They Are the Biggest Eczema Development in Years | National Eczema Association
![Pharmaceuticals | Free Full-Text | Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies Pharmaceuticals | Free Full-Text | Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies](https://pub.mdpi-res.com/pharmaceuticals/pharmaceuticals-15-00048/article_deploy/html/images/pharmaceuticals-15-00048-ag.png?1640942350)
Pharmaceuticals | Free Full-Text | Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
![Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41584-021-00726-8/MediaObjects/41584_2021_726_Fig1_HTML.png)
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach | Nature Reviews Rheumatology
![A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring | SpringerLink A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-023-00892-5/MediaObjects/13555_2023_892_Fig1_HTML.png)
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring | SpringerLink
![Treating inflammation with the Janus Kinase inhibitor CP-690,550: Trends in Pharmacological Sciences Treating inflammation with the Janus Kinase inhibitor CP-690,550: Trends in Pharmacological Sciences](https://www.cell.com/cms/attachment/a707b3e7-a92c-4a8e-b0e3-0112c506c162/gr1.jpg)
Treating inflammation with the Janus Kinase inhibitor CP-690,550: Trends in Pharmacological Sciences
![Hypoglycaemia following JAK inhibitor treatment in patients with diabetes | Annals of the Rheumatic Diseases Hypoglycaemia following JAK inhibitor treatment in patients with diabetes | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/81/4/597/F1.large.jpg)
Hypoglycaemia following JAK inhibitor treatment in patients with diabetes | Annals of the Rheumatic Diseases
![The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage](https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c74fdbbdbb891b12a39e36/largeThumb/the-potential-of-jak-stat-pathway-inhibition-as-a-new-treatment-strategy-to-control-cytokine-release-syndrome-in-covid-19.jpg)
The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19 | Biological and Medicinal Chemistry | ChemRxiv | Cambridge Open Engage
![The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions - Journal of Allergy and Clinical Immunology The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions - Journal of Allergy and Clinical Immunology](https://www.jacionline.org/cms/asset/e4e0edfa-47b0-4dac-9e26-86e52ebf2400/gr1.jpg)